Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors -- drugs that take the brakes ...

1. Compared to receiving intravenous (directly into a vein (IV)) anti-cancer therapy in hospital outpatient clinics, we are uncertain whether receiving the same therapy at home affects the management ...

Key Takeaways Immunotherapy is as effective in seniors as in younger peopleSeniors’ immune systems are weaker, and thus less ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

Persistent Epstein-Barr virus DNA or its resurgence during treatment was associated with worse survival in patients with ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Mar. 3, 2025 — Researchers have shown how a low carbohydrate diet can worsen the DNA-damaging effects of some gut microbes to cause colorectal cancer. The study compared the effects of three ...

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...